Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates
August 12, 2024 08:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial...
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
July 25, 2024 07:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the...
GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research
July 15, 2024 08:00 ET
|
Checkpoint Therapeutics, Inc
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy, Immuncell-LC YONGIN, South Korea and WALTHAM,...
Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
July 02, 2024 08:00 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has...
Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab
July 02, 2024 07:00 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has...
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
June 24, 2024 07:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has...
CKPT DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action – CKPT
June 03, 2024 19:08 ET
|
The Rosen Law Firm PA
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) between March...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint
June 03, 2024 12:21 ET
|
Faruqi & Faruqi LLP
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. (“Checkpoint” or...
DEADLINE ALERT for HRT and CKPT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
June 03, 2024 11:15 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, June 03, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
ROSEN, A LEADING LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action – CKPT
May 30, 2024 14:06 ET
|
The Rosen Law Firm PA
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) between March...